114 related articles for article (PubMed ID: 20673499)
61. Combined prognostic value of both RelA and IkappaB-alpha expression in human non-small cell lung cancer.
Zhang D; Jin X; Wang F; Wang S; Deng C; Gao Z; Guo C
Ann Surg Oncol; 2007 Dec; 14(12):3581-92. PubMed ID: 17899287
[TBL] [Abstract][Full Text] [Related]
62. Optimal combination of immunohistochemical markers for subclassification of non-small cell lung carcinomas: A tissue microarray study of poorly differentiated areas.
Noh S; Shim H
Lung Cancer; 2012 Apr; 76(1):51-5. PubMed ID: 21978426
[TBL] [Abstract][Full Text] [Related]
63. In NSCLC, VEGF-A response to hypoxia may differ between squamous cell and adenocarcinoma histology.
Eilertsen M; Pettersen I; Andersen S; Martinez I; Donnem T; Busund LT; Bremnes RM
Anticancer Res; 2012 Nov; 32(11):4729-36. PubMed ID: 23155236
[TBL] [Abstract][Full Text] [Related]
64. PIAS3, SHP2 and SOCS3 Expression patterns in Cervical Cancers: Relevance with activation and resveratrol-caused inactivation of STAT3 signaling.
Zhang P; Yang B; Yao YY; Zhong LX; Chen XY; Kong QY; Wu ML; Li C; Li H; Liu J
Gynecol Oncol; 2015 Dec; 139(3):529-35. PubMed ID: 26432044
[TBL] [Abstract][Full Text] [Related]
65. Maspin, VEGF and p53 expression in small biopsies of primary advanced lung cancer and relationship with clinicopathologic parameters.
Bircan A; Bircan S; Kapucuoglu N; Songur N; Ozturk O; Akkaya A
Pathol Oncol Res; 2010 Dec; 16(4):553-61. PubMed ID: 20349288
[TBL] [Abstract][Full Text] [Related]
66. Expression of high mobility group box - B1 (HMGB-1) and matrix metalloproteinase-9 (MMP-9) in non-small cell lung cancer (NSCLC).
Wang JL; Wu DW; Cheng ZZ; Han WZ; Xu SW; Sun NN
Asian Pac J Cancer Prev; 2014; 15(12):4865-9. PubMed ID: 24998555
[TBL] [Abstract][Full Text] [Related]
67. Increased NDRG1 expression is associated with advanced T stages and poor vascularization in non-small cell lung cancer.
Fan C; Yu J; Liu Y; Xu H; Wang E
Pathol Oncol Res; 2012 Jul; 18(3):549-56. PubMed ID: 20853080
[TBL] [Abstract][Full Text] [Related]
68. Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent.
Gouyer V; Conti M; Devos P; Zerimech F; Copin MC; Créme E; Wurtz A; Porte H; Huet G
Cancer; 2005 Apr; 103(8):1676-84. PubMed ID: 15754326
[TBL] [Abstract][Full Text] [Related]
69. Evaluation of immunohistochemical markers in non-small cell lung cancer by unsupervised hierarchical clustering analysis: a tissue microarray study of 284 cases and 18 markers.
Au NH; Cheang M; Huntsman DG; Yorida E; Coldman A; Elliott WM; Bebb G; Flint J; English J; Gilks CB; Grimes HL
J Pathol; 2004 Sep; 204(1):101-9. PubMed ID: 15307143
[TBL] [Abstract][Full Text] [Related]
70. Beclin 1 and p62 expression in non-small cell lung cancer: relation with malignant behaviors and clinical outcome.
Wang X; Du Z; Li L; Shi M; Yu Y
Int J Clin Exp Pathol; 2015; 8(9):10644-52. PubMed ID: 26617774
[TBL] [Abstract][Full Text] [Related]
71. Clinical significance and biological role of cancer-derived Type I collagen in lung and esophageal cancers.
Fang S; Dai Y; Mei Y; Yang M; Hu L; Yang H; Guan X; Li J
Thorac Cancer; 2019 Feb; 10(2):277-288. PubMed ID: 30604926
[TBL] [Abstract][Full Text] [Related]
72. [Message RNA expression of LUNX, CK19 and CEA genes in NSCLC with micrometastasis in lymph nodes].
Wang WB; Cui YG; Yao SY
Zhonghua Zhong Liu Za Zhi; 2008 Feb; 30(2):121-4. PubMed ID: 18646695
[TBL] [Abstract][Full Text] [Related]
73. [The cyclin A, B1, D1 and E expression in advanced non-small cell lung cancer--stages IIIB-IV (preliminary report)].
Kosacka M; Piesiak P; Porebska I; Korzeniewska A; Jankowska R
Pol Merkur Lekarski; 2011 Apr; 30(178):253-8. PubMed ID: 21595169
[TBL] [Abstract][Full Text] [Related]
74. Metastasis-associated in colon cancer-1 and aldehyde dehydrogenase 1 are metastatic and prognostic biomarker for non-small cell lung cancer.
Zhou L; Yu L; Zhu B; Wu S; Song W; Gong X; Wang D
BMC Cancer; 2016 Nov; 16(1):876. PubMed ID: 27832750
[TBL] [Abstract][Full Text] [Related]
75. Cyclin A and Cyclin E expression in resected non-small cell lung cancer stage I-IIIA.
Kosacka M; Piesiak P; Porebska I; Korzeniewska A; Dyla T; Jankowska R
In Vivo; 2009; 23(4):519-25. PubMed ID: 19567385
[TBL] [Abstract][Full Text] [Related]
76. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.
Dong X; Lin D; Low C; Vucic EA; English JC; Yee J; Murray N; Lam WL; Ling V; Lam S; Gout PW; Wang Y
J Thorac Oncol; 2013 Feb; 8(2):161-70. PubMed ID: 23287853
[TBL] [Abstract][Full Text] [Related]
77. Expression of MDA-7/IL-24 and its clinical significance in resected non-small cell lung cancer.
Ishikawa S; Nakagawa T; Miyahara R; Kawano Y; Takenaka K; Yanagihara K; Otake Y; Katakura H; Wada H; Tanaka F
Clin Cancer Res; 2005 Feb; 11(3):1198-202. PubMed ID: 15709189
[TBL] [Abstract][Full Text] [Related]
78. SHP2 inhibitor specifically suppresses the stemness of KRAS-mutant non-small cell lung cancer cells.
Jiang L; Xu W; Chen Y; Zhang Y
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):3231-3238. PubMed ID: 31373232
[TBL] [Abstract][Full Text] [Related]
79. The prognostic significance of SHP2 and its binding protein Hook1 in non-small cell lung cancer.
He L; Li Y; Huang X; Cheng H; Ke Y; Wang L
Onco Targets Ther; 2019; 12():5897-5906. PubMed ID: 31413587
[TBL] [Abstract][Full Text] [Related]
80. Src homology phosphotyrosyl phosphatase-2 expression is an independent negative prognostic factor in human breast cancer.
Muenst S; Obermann EC; Gao F; Oertli D; Viehl CT; Weber WP; Fleming T; Gillanders WE; Soysal SD
Histopathology; 2013 Jul; 63(1):74-82. PubMed ID: 23672411
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
